摘要
通过异种移植物抗宿主反应(XGVHR)的动物模型筛选出黄芪促免疫的有效成份 F3。该成份在体外 XGVHR 试验中显示对癌症患者淋巴细胞功能有完全性免疫恢复作用(反应结节从57.80±16.44mm^3到148.95±40.84mm^3),在体内动物模型试验中可显示出全部逆转因环磷酰胺而造成的免疫抑制现象,提示黄芪成份在免疫治疗中可能是一个很有希望的生物反应调节剂。
Through the process of fractionation,purification by gel filtration chromatography and there- after the screening with an in vitro local xenogeneic graft-versus-host reaction(XGVHR)model,a fraction was identified as a potent immunorestorative agent and was designated'Fraction 3'(F3). Using the XGVHR in vitro as a model assay for T cell function again,F3 was studied on mononu- clear cells(MNC)from 13 cancer patients and exhibited significant immunorestorative activity,with an increase in local XGVHR(compared to untreated cells)of 151.34±46.02 mm^3 vs 57.80±16.44 mm^3, P<0.001.The in vitro augmented immune reactions in(?)ced by F3 in cancer patients also significant- ly exceeded the local XGVHR observed in the untreated MNC derived from 9 normal donor controls (94.15±9.16 mm^3,P<0.005).In a newly developed in vivo XGVHR animal model,pretreatment of rats with F3 resulted in a significant abrogation of the local XGVHR with a reversal of the immunosuppressive effect of eyclophosphamide from 99.42±9.2 mm^3(positive control)to 39.78±8.3 mm^3(P<0.001).This reversal was complete as the volume of the abrogated local XGVHR was comparable to that of the negative control(no cyclophosphamide-priming,saline injection only) 34.79±5.69 mm^3(P>0.1).These results suggest that F3 retained the immunopotentiating activity of the original crude extract and form the rational basis for the use of Astragalus in immunotherapy.
出处
《中西医结合杂志》
CSCD
北大核心
1989年第6期351-354,326,共4页
